View the full transcript and gain access to JoVE Science Education videos
Q1: What is the difference between heritable and sporadic genetic diseases?
Heritable genetic diseases are caused by mutations passed down from generation to generation through families, such as hemophilia. Sporadic genetic diseases, like many cancers, arise from mutations that occur during an individual's lifetime and are not inherited. Understanding this distinction helps geneticists determine whether family history or environmental factors play a greater role in disease development.
Q2: How do oncogenes and tumor suppressors contribute to cancer development differently?
Oncogenes are mutated genes whose encoded proteins gain new or enhanced functionalities, leading to uncontrolled cell proliferation. Tumor suppressors, by contrast, only cause cancer when both copies are mutated, resulting in loss-of-function of the encoded protein. This two-hit hypothesis explains why tumor suppressors require dual mutations, whereas oncogenes need only one mutated copy to promote cancer.
Q3: What are the main techniques used to identify disease-causing mutations?
Geneticists use several approaches including SNP genotyping to detect single nucleotide differences, Sanger sequencing for candidate genes, and high-throughput next-generation sequencing for large-scale analyses. Genome-wide association studies identify SNPs with different frequencies in affected versus control populations. Cytogenetics techniques like karyotyping and fluorescence in situ hybridization detect structural variations within the genome.
Q4: How do the common disease/common variant and multiple rare variant hypotheses differ?
The common disease/common variant hypothesis suggests that many genetic variants common in the population each have modest effects on disease risk. The multiple rare variant hypothesis argues that relatively rare variants with large effects are more important for disease development. These competing models shape how researchers design studies to identify genetic factors in complex diseases like Parkinson's and heart disease.
Q5: What historical discovery established the link between genes and enzyme function in disease?
Archibald Garrod discovered alkaptonuria in 1896, proposing that patients lacked an enzyme involved in protein breakdown. Building on this work, George Beadle and Edward Tatum formulated the one gene, one enzyme hypothesis, suggesting that each gene specifies production of one enzyme controlling a single metabolic pathway step. This foundational concept connected genetic mutations to metabolic disease mechanisms.
Q6: How do researchers use family pedigrees combined with sequencing to identify disease mutations?
Researchers study family pedigrees to trace inheritance patterns and identify affected individuals, then sequence candidate genes in these families to detect mutations. Mutations classified as de novo are spontaneous and not inherited from parents. This approach successfully identified schizophrenia-associated mutations and demonstrates how combining classical genetic analysis with modern sequencing reveals disease-causing variants.
Q7: How is DNA sequencing applied in clinical cancer diagnosis today?
Clinicians extract and fragment DNA from tumor samples, then isolate protein-coding exons using chemically tagged complementary oligonucleotides and high-affinity capture proteins. The captured DNA is sequenced and compared to healthy control samples to identify cancer-causing mutations. This targeted sequencing approach enables personalized diagnosis and informs treatment decisions for cancer patients.
Copyright © 2026 MyJoVE Corporation. All rights reserved